296 related articles for article (PubMed ID: 15185124)
1. WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.
Church MW; Blakley BW; Burgio DL; Gupta AK
J Assoc Res Otolaryngol; 2004 Sep; 5(3):227-37. PubMed ID: 15185124
[TBL] [Abstract][Full Text] [Related]
2. The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity.
Church MW; Kaltenbach JA; Blakley BW; Burgio DL
Hear Res; 1995 Jun; 86(1-2):195-203. PubMed ID: 8567417
[TBL] [Abstract][Full Text] [Related]
3. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster.
Kaltenbach JA; Church MW; Blakley BW; McCaslin DL; Burgio DL
Otolaryngol Head Neck Surg; 1997 Nov; 117(5):493-500. PubMed ID: 9374173
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the protective effects of amifostine against cisplatin-induced toxicity.
Hussain AE; Blakley BW; Nicolas M; Balderston J
J Otolaryngol; 2003 Oct; 32(5):294-7. PubMed ID: 14974858
[TBL] [Abstract][Full Text] [Related]
5. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
6. An Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect.
Bielefeld EC; Tanaka C; Chen GD; Coling D; Li M; Henderson D; Fetoni AR
Anticancer Drugs; 2013 Jan; 24(1):43-51. PubMed ID: 22828384
[TBL] [Abstract][Full Text] [Related]
7. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
8. A low-dose regimen of cisplatin before high-dose cisplatin potentiates ototoxicity.
Harrison RT; DeBacker JR; Bielefeld EC
Laryngoscope; 2015 Feb; 125(2):E78-83. PubMed ID: 25267530
[TBL] [Abstract][Full Text] [Related]
9. Ototoxicity of 12 mg/kg cisplatin in the Fischer 344/NHsd rat using multiple dosing strategies.
Harrison RT; Seiler BM; Bielefeld EC
Anticancer Drugs; 2016 Sep; 27(8):780-6. PubMed ID: 27467178
[TBL] [Abstract][Full Text] [Related]
10. Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma.
Rubin JS; Wadler S; Beitler JJ; Haynes H; Rozenblit A; McGill F; Goldberg G; Runowicz C
J Laryngol Otol; 1995 Aug; 109(8):744-7. PubMed ID: 7561498
[TBL] [Abstract][Full Text] [Related]
11. [Amifostine otoprotection to cisplatin ototoxicity: a guinea pig study using otoacoustic emission distortion products (DPOEA) and scanning electron microscopy].
Hyppolito MA; de Oliveira AA; Lessa RM; Rossato M
Braz J Otorhinolaryngol; 2005; 71(3):268-73. PubMed ID: 16446928
[TBL] [Abstract][Full Text] [Related]
12. AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity.
Cooper LB; Chan DK; Roediger FC; Shaffer BR; Fraser JF; Musatov S; Selesnick SH; Kaplitt MG
Otol Neurotol; 2006 Jun; 27(4):484-90. PubMed ID: 16791039
[TBL] [Abstract][Full Text] [Related]
13. Targeting nitrative stress for attenuating cisplatin-induced downregulation of cochlear LIM domain only 4 and ototoxicity.
Jamesdaniel S; Rathinam R; Neumann WL
Redox Biol; 2016 Dec; 10():257-265. PubMed ID: 27821327
[TBL] [Abstract][Full Text] [Related]
14. Effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in adult guinea pigs.
Shafik AG; Elkabarity RH; Thabet MT; Soliman NB; Kalleny NK
Auris Nasus Larynx; 2013 Feb; 40(1):51-60. PubMed ID: 22884636
[TBL] [Abstract][Full Text] [Related]
15. Epicatechin protects the auditory organ by attenuating cisplatin-induced ototoxicity through inhibition of ERK.
Lee JS; Kang SU; Hwang HS; Pyun JH; Choung YH; Kim CH
Toxicol Lett; 2010 Dec; 199(3):308-16. PubMed ID: 20883750
[TBL] [Abstract][Full Text] [Related]
16. Lovastatin protects against cisplatin-induced hearing loss in mice.
Fernandez K; Spielbauer KK; Rusheen A; Wang L; Baker TG; Eyles S; Cunningham LL
Hear Res; 2020 Apr; 389():107905. PubMed ID: 32062294
[TBL] [Abstract][Full Text] [Related]
17. Friend or foe? Effect of oral resveratrol on cisplatin ototoxicity.
Olgun Y; Kırkım G; Kolatan E; Kıray M; Bagrıyanık A; Olgun A; Kızmazoglu DC; Ellıdokuz H; Serbetcıoglu B; Altun Z; Aktas S; Yılmaz O; Günerı EA
Laryngoscope; 2014 Mar; 124(3):760-6. PubMed ID: 23900991
[TBL] [Abstract][Full Text] [Related]
18. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
[TBL] [Abstract][Full Text] [Related]
19. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
20. Protective role of resveratrol against cisplatin induced ototoxicity in guinea pigs.
Yumusakhuylu AC; Yazici M; Sari M; Binnetoglu A; Kosemihal E; Akdas F; Sirvanci S; Yuksel M; Uneri C; Tutkun A
Int J Pediatr Otorhinolaryngol; 2012 Mar; 76(3):404-8. PubMed ID: 22261612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
